PDS Biotech Raises $11.3M in PIPE Led by Dr. Soon-Shiong, Adds High-Profile Board Member
Event summary
- PDS Biotech closed an initial $11.3M PIPE round led by Nant Capital, with potential for an additional $11M at a future milestone.
- Dr. Patrick Soon-Shiong, founder of NantWorks, joined PDS Biotech's board alongside James Banaag, CFO of NantBio.
- The funding will support late-stage development of PDS0301, an IL-12 immunocytokine showing promise in treating metastatic colorectal cancer.
- NantWorks gained a one-year exclusive option to negotiate a license for PDS0101, an HPV-targeted immunotherapy.
The big picture
This financing and board appointment signal growing confidence in PDS Biotech's immunotherapy platform, particularly as it targets aggressive cancer types resistant to existing treatments. Dr. Soon-Shiong's track record in developing successful cancer therapies adds credibility, while the contingent financing structure reflects both opportunity and execution risk. The deal underscores the industry's push toward targeted immunotherapies and the strategic importance of high-profile investor backing in biotech.
What we're watching
- Clinical Validation
- Whether PDS0301 can maintain its promising Phase 2 results in late-stage trials for metastatic colorectal cancer.
- Strategic Alignment
- How Dr. Soon-Shiong's involvement will shape PDS Biotech's R&D priorities and partnership strategy.
- Execution Risk
- The pace at which PDS Biotech can advance its pipeline while managing the complexities of multiple financing milestones.
Related topics